STOCK TITAN
  1. Home
  2. News
  3. AKYA

Akoya BioSciences, Inc. - AKYA STOCK NEWS

Welcome to our dedicated page for Akoya BioSciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya BioSciences stock.

Akoya BioSciences, Inc. (Nasdaq: AKYA) is a leading life sciences technology company pioneering spatial biology solutions that transform discovery, clinical research, and diagnostics. Akoya is committed to advancing the science of imaging with its comprehensive platforms, including PhenoCycler® and PhenoImager®, that perform deep proteomic profiling and spatial phenotyping. These cutting-edge platforms enable researchers to analyze tissue samples with high precision, providing insights into cellular interactions and disease mechanisms.

In 2024, Akoya announced preliminary unaudited revenue for Q4 2023 between $25.5 million and $26.5 million, marking a significant increase from Q4 2022. For the fiscal year 2023, revenues are expected to reach between $95.6 million and $96.6 million.

Akoya's portfolio includes innovative products like PhenoCode™ Panels, PhenoCycler®, and PhenoImager® HT, which support high-throughput and high-parameter tissue analysis. Notably, the company has recently partnered with Thermo Fisher Scientific to enhance its spatial multiomic workflow by integrating ViewRNA technology.

The company's technology has attracted significant attention in the scientific community, with its systems cited in over 1,300 publications as of March 2024. Akoya has also formed strategic partnerships and collaborations, including with the Queensland Spatial Biology Centre and organizations like BostonGene and NeraCare, enhancing the application of its platforms in various fields of research and clinical diagnostics.

Financially, Akoya aims for substantial revenue growth in 2024 with projections exceeding 20%, supported by its robust balance sheet and strategic initiatives like the new Manufacturing Center of Excellence in Marlborough, MA. This facility is expected to streamline operations, improve supply chain efficiency, and meet the growing demand for spatial biology solutions.

If you're a scientist or software engineer passionate about revolutionizing imaging science, Akoya BioSciences offers an exciting environment for innovation. For more information, contact Akoya at info@akoyabio.com.

News

Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook

Rhea-AI Summary
Akoya Biosciences, Inc. (Nasdaq: AKYA) announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2023. Revenue for Q4 2023 is expected to be between $25.5 million and $26.5 million, compared to $21.2 million for Q4 2022. For the fiscal year of 2023, revenue is expected to be between $95.6 million and $96.6 million, compared to $74.9 million for 2022. Year-end 2023 projected cash balance is expected to be between $83.0 million and $85.0 million. Akoya expects full year 2024 revenue to grow 20%+ and projects achieving operating cash flow breakeven by year end 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News

Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow

Rhea-AI Summary
Akoya Biosciences, Inc. (NASDAQ: AKYA) has entered into a license and distribution agreement with Thermo Fisher Scientific, Inc. to combine their spatial biology solutions with Thermo Fisher's ViewRNA In Situ Hybridization Assays, enabling rapid, whole-slide imaging of RNA and protein biomarkers in tissue samples. This partnership aims to provide researchers with a more comprehensive understanding of tumor progression, molecules, and biologics, facilitating the development of more accurate biomarker signatures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform

Rhea-AI Summary
Akoya Biosciences, Inc. (NASDAQ: AKYA) collaborates with Enable Medicine to announce the availability of MaxFuse, an advanced algorithm co-developed in the laboratory of Dr. Garry Nolan for integrating multiomic single-cell and spatial datasets. Recent technology advancements have enabled analyses of the proteome, metabolome, transcriptome, and epigenome both spatially and at the single-cell level. The MaxFuse algorithm provides a reliable, fast, cost-effective, and scientifically powerful means to integrate spatial proteomic data with single-cell transcriptomic and epigenomic data sets. The development, co-developers, and applications of MaxFuse were described in recent Nature and Nature Biotechnology publications. Akoya’s customers can access MaxFuse through the Enable Medicine AI-Cloud Platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Akoya Biosciences, Inc. (Nasdaq: AKYA) will be participating in the 42nd Annual J.P. Morgan Healthcare Conference. CEO Brian McKelligon is scheduled to present on January 10th, 2024. A live and archived webcast of the event will be available on the Akoya website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
conferences
-
News

Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance

Rhea-AI Summary
Akoya Biosciences, Inc. (Nasdaq: AKYA) announced Q3 2023 revenue of $25.2 million, marking a 34% year-over-year growth. The company also reiterated its FY 2023 revenue guidance range of $95-98 million. The financial results show strong performance, with total revenue, product revenue, and gross profit all increasing significantly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.9%
Tags
none
-
News

Akoya to Participate at Three Upcoming Investor Conferences

Rhea-AI Summary
Akoya Biosciences, Inc. (Nasdaq: AKYA) will be participating in three upcoming investor conferences: Stephens Annual Investment Conference, Canaccord Genuity 2023 MedTech, Diagnostics and Digital Health & Services Forum, and Piper Sandler 35th Annual Healthcare Conference. The fireside chats will cover various topics related to the company's spatial biology solutions. The events will be webcasted live and archived on the Akoya website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.92%
Tags
conferences
News

Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023

Rhea-AI Summary
Akoya Biosciences Inc. will showcase its latest Spatial Biology 2.0 solutions and ultrahigh-plex spatial phenotyping data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The company will highlight its new PhenoCycler-Fusion 2.0 and PhenoImager HT 2.0 platforms, which offer advancements in speed and scale for spatial biology research. Akoya's global network of CROs will also be exhibiting at SITC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
none
-
News

Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures

Rhea-AI Summary
Akoya Biosciences and The University of Queensland's Frazer Institute have mapped the spatial proteome of head and neck squamous cell carcinoma (HNSCC) using ultrahigh-plex spatial phenotyping. The study reveals the heterogeneity of head and neck cancers and provides insights into the mechanistic basis of variable clinical responses. The research highlights the enrichment of specialized immune cell subsets and metabolic and stress signatures within specific spatial domains in the tumor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
none
-
News

Akoya to Report Third Quarter 2023 Financial Results on November 8th, 2023

Rhea-AI Summary
Akoya Biosciences to release Q3 2023 financial results on November 8th
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.1%
Tags
conferences earnings
News

Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms

Rhea-AI Summary
Akoya Biosciences highlights industry-leading scale and speed in spatial biology workflows with PhenoCycler-Fusion 2.0 and PhenoImager HT 2.0 upgrades
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.95%
Tags
none

FAQ

What is the current stock price of Akoya BioSciences (AKYA)?

The current stock price of Akoya BioSciences (AKYA) is $2.49 as of December 20, 2024.

What is the market cap of Akoya BioSciences (AKYA)?

The market cap of Akoya BioSciences (AKYA) is approximately 118.0M.

What does Akoya BioSciences, Inc. do?

Akoya BioSciences, Inc. specializes in spatial biology solutions, enabling advanced tissue analysis and spatial phenotyping for research and clinical diagnostics.

What are Akoya's core products?

Akoya's core products include the PhenoCycler® platform, PhenoImager® instruments, and PhenoCode™ Panels, which support high-parameter tissue analysis and spatial phenotyping.

How did Akoya perform financially in 2023?

For the fiscal year 2023, Akoya's revenue is expected to range between $95.6 million and $96.6 million, showing significant growth compared to the previous year.

Who are some of Akoya's key partners?

Akoya has partnered with notable organizations like Thermo Fisher Scientific, BostonGene, and NeraCare to enhance its spatial biology capabilities and applications.

What recent achievements has Akoya announced?

Recent achievements include a successful partnership with Thermo Fisher Scientific, positive clinical data presentations, and the opening of a new manufacturing facility in Marlborough, MA.

How many publications have cited Akoya's technology?

As of March 2024, Akoya’s technology has been cited in over 1,300 scientific publications.

What is Akoya's financial outlook for 2024?

Akoya projects full-year 2024 revenue growth exceeding 20% and aims to achieve operating cash flow breakeven by year-end.

What is the significance of the new Manufacturing Center of Excellence?

The new facility in Marlborough, MA, will enhance Akoya's operational efficiency, meet growing demand, and improve supply chain management for its spatial biology solutions.

Who should consider working at Akoya BioSciences?

Scientists and software engineers interested in revolutionizing imaging science and advancing spatial biology should consider opportunities at Akoya BioSciences.

How can one contact Akoya BioSciences for more information?

You can contact Akoya BioSciences via email at info@akoyabio.com for more information.

Stock AKYA logo
Akoya BioSciences, Inc.

Nasdaq:AKYA

AKYA Rankings

#4278 Ranked by Market Cap
N/A Ranked by Dividends

AKYA Stock Data

117.96M
25.62M
11.09%
70.19%
3.24%
Medical Instruments & Supplies
Laboratory Analytical Instruments
Link
United States of America
MARLBOROUGH